Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
SPYG vs XLV: how they differ
SPYG and XLV hold 6% of their weight in the same names, and XLV returned more over the year.
State Street(R) SPDR(R) Portfolio S&P 500(R) Growth ETF and State Street(R) Health Care Select Sector SPDR(R) ETF.
What they hold in common
By the books each fund has filed, SPYG and XLV hold 6% of their money in the same securities at the same weight.
| Holding | SPYG | XLV |
|---|---|---|
| Eli Lilly & Co | 2.67% | 16.56% |
| Johnson & Johnson | 1.02% | 10.67% |
| AbbVie Inc | 0.58% | 7.76% |
| Intuitive Surgical Inc | 0.40% | 2.46% |
| Amgen Inc | 0.38% | 3.41% |
| Gilead Sciences Inc | 0.24% | 2.74% |
| HCA Healthcare Inc | 0.17% | 1.06% |
| Stryker Corp | 0.13% | 1.90% |
| Boston Scientific Corp | 0.12% | 1.11% |
| IDEXX Laboratories Inc | 0.12% | 0.72% |
| Edwards Lifesciences Corp | 0.07% | 0.91% |
| Incyte Corp | 0.05% | 0.33% |
| Only in SPYG | Only in XLV |
|---|---|
| NVIDIA Corp 13.66% | UnitedHealth Group Inc 6.59% |
| Microsoft Corp 7.81% | Merck & Co Inc 5.54% |
| Apple Inc 5.99% | Thermo Fisher Scientific Inc 3.25% |
| Alphabet Inc 5.91% | Abbott Laboratories 2.76% |
| Broadcom Inc 5.04% | Pfizer Inc 2.40% |
| Alphabet Inc 4.71% | CVS Health Corp 2.30% |
| Micron Technology Inc 3.67% | Vertex Pharmaceuticals Inc 2.20% |
| Meta Platforms Inc 3.49% | Danaher Corp 2.10% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| SPYG State Street(R) SPDR(R) Portfolio S&P 500(R) Growth ETF | XLV State Street(R) Health Care Select Sector SPDR(R) ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | State Street | State Street |
| What it is | SPDR Portfolio S&P 500 Growth | Health care |
| Total return, 1 year | +17.9% | +20.4% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +0.4 pts | +2.9 pts |
| Expense ratio | 0.04% | 0.08% |
| Already in the S&P 500 | 100.0% | 100.0% |
| Holdings | 147 | 59 |
SPYG in plain words
SPYG is an index equity fund tracking the SPDR Portfolio S&P 500 Growth. Over the year to Sep 11, 2026 it returned +17.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.04% a year. By its holdings filed for Jun 30, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 147 positions, with the top ten at 56.4%.
XLV in plain words
XLV is an index equity fund tracking the Health care. Over the year to Sep 11, 2026 it returned +20.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.08% a year. By its holdings filed for Jun 30, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 59 positions, with the top ten at 61.7%. It sat 5.9% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, SPYG or XLV?
- In the year to Sep 12, 2026, with distributions reinvested, SPYG returned +17.9% and XLV returned +20.4%, so XLV returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, SPYG or XLV?
- SPYG charges 0.04% a year and XLV charges 0.08%, so SPYG is cheaper. Fees come from each fund's prospectus.
- How much do SPYG and XLV overlap with the S&P 500?
- By their latest filed holdings, 100% of SPYG and 100% of XLV by weight is stocks the S&P 500 already holds. Between the two funds, 6% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, SPYG against XLV, data as of Sep 12, 2026. https://etfiq.com/compare/any/SPYG-XLV Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources